Novo Nordisk stock news
On October 26, 2026, the Milan Central Division of the Unified Patent Court (UPC) issued an order dismissing a preliminary objection raised by Novo Nordisk in an ongoing patent dispute initiated by Sandoz (case ID: UPC_CFI_2221/2026). The dispute concerns European Patent EP 3 689 365, which covers once--weekly 1.0 mg semaglutide formulations—the active pharmaceutical ingredient underlying Ozempic, Wegovy, and Rybelsus. Sandoz filed the revocation action alleging added matter and lack of inventive step, while petitioning the court to bar Novo Nordisk from withdrawing its patent text before the European Patent Office to circumvent adverse validity findings while maintaining divisional applications. By affirming its jurisdiction over such withdrawal practices, the court signaled greater regulatory and litigation exposure for Novo Nordisk's European patent defense strategy covering its core cardiometabolic portfolio.